ArticleThe American journal of case reports2026
Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell lymphoma associated with chronic hepatitis C infection. It typically presents with diffuse splenomegaly rather than a focal splenic mass. Focal splenic lesions with vascular enhancement patterns are usually due to vascular tumors which may be benign or malignant, examples of which include sclerosing angiomatoid nodular transformation, hemangiomas, or angiosarcomas. CASE REPORT A 60-year-old man with newly diagnosed hepatitis C-related Child-Pugh A cirrhosis was incidentally found to have a splenic lesion during index abdominal imaging. He was initiated on hepatitis C treatment and successfully achieved a sustained virologic response. Despite viral eradication, serial imaging over 3 years demonstrated a sudden increase in size from 3.3 cm to 5.7 cm. Multiphasic computed tomography (CT) of the abdomen demonstrated a progressive peripheral-to-central enhancement pattern, mimicking a vascular splenic tumor. A review by a multidisciplinary tumor board recommended splenectomy due to progressive enlargement, rupture risk, and inability to exclude a malignant lesion. Histopathological examination revealed SMZL with extensive central infarction and granulomatous reaction, confirming the diagnosis with characteristic biphasic architecture and CD20-positive B-cell populations. No features of aggressive transformation were identified. CONCLUSIONS Our case highlights an unusual presentation of SMZL as a focal splenic mass, rather than diffuse splenomegaly, which grew despite hepatitis C eradication. Tumor infarction and slow organization can produce radiologic features that mimic vascular splenic lesions. This demonstrates the importance of clinicoradiological-pathological correlation and the necessity of histological confirmation in indeterminate splenic masses to avoid delays in management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.